Interested in the Janssen COVID 19 Vaccine?

This page contains information for the Janssen COVID 19 vaccine.

Please check in frequently as information will be posted as it becomes available.

URGENT: CDC and FDA Pause Use of Johnson & Johnson COVID-19 Vaccine - April 16, 2021

Safety is our top priority. In accordance with the CDC and FDA, the City of Chicago paused the use of the Johnson & Johnson (J&J) vaccine while the CDC and FDA reviews all of the information. The ACIP held an emergency meeting on April 14 and recommended to continue the pause of J&J while more data is collected, and they will reconvene when sufficient data becomes available, currently scheduled for Friday, April 23. Vaccination remains critical to protecting Chicagoans and we’ll share more information as it becomes available.

Background on the Johnson & Johnson (Janssen) COVID-19 Vaccine

The Johnson & Johnson COVID-19 vaccine was officially granted Emergency Use Authorization (EUA) by the FDA on February 27, 2021 and recommended by the CDC Advisory Committee on Immunization Practices (ACIP) on February 28, 2021. Compared to mRNA platform vaccines previously authorized for emergency use in the US, the Johnson & Johnson vaccine is a non-replicating adenoviral vector vaccine which is considered an inactivated viral vaccine. The trial occurred when new, highly transmissible variants were emerging. Across all sites, the vaccine was approximately 66% effective in preventing moderate to severe COVID-19, 85% effective in preventing severe/critical COVID-19 and 100% effective in preventing hospitalization. The vaccine has an excellent safety profile; side effects were generally mild, lasting 1-2 days. Owing to differences in research protocols and settings, direct comparison of efficacy with other EUA vaccines is not feasible.

Similar to the Pfizer-BioNTech and Moderna COVID-19 vaccines, initial supply of the Johnson & Johnson vaccine will be limited. Vaccinators must report all serious adverse events, vaccine administration errors, hospitalizations, and deaths to the FDA and CDC through the Vaccine Adverse Event Reporting System (VAERS). Also ensure that V-safe (a voluntary smartphone-based tool that uses text messaging and web surveys to check in with people who have been vaccinated to identify potential side effects after COVID19 vaccination) is available to vaccine recipients.

Key Messages about Johnson & Johnson (Janssen) COVID-19 vaccine:

  • Janssen’s single dose vaccine has been shown to prevent COVID-19 illness, hospitalization, and death. Reported side effects to date are typically milder than with other currently approved vaccines. As with any vaccine, adverse reactions, including anaphylaxis, may occur.
  • The vaccine was studied in multiple countries, including South Africa and Brazil, both places where variants of COVID-19 have emerged.
  • This vaccine can be stored at refrigerator temperatures (as well as in the freezer for up to 2 months) and does not require reconstitution— so it is easy to transport, store and administer, and allows for expanded availability in most community settings and mobile sites.
  • We now have three vaccine with impressive efficacy— more people in Chicago will be able to get vaccinated, including individuals (e.g., healthcare workers) who have declined mRNA vaccines.
  • Remember to strongly encourage all authorized COVID-19 vaccines in this lime of limited supply and growing variant prevalence; learn to discuss the difference between viral vector and mRNA vaccines.

COVID-19 Vaccine Contact Information

 

Please direct all questions to COVID19vaccine@cityofchicago.org.

 

Please visit the Illinois Department of Public Health I-CARE website for information on enrolling a facility or individual in I-CARE: https://www.dph.illinois.gov/topics-services/prevention-wellness/immunization/icare

 

For information on the vaccine please go to: www.chicago.gov/covidvax.

Announcements

As of April 19, all Chicagoans age 16 and up are eligible for vaccination in Chicago (phase 2).

 

The Johnson & Johnson COVID-19 vaccine was officially granted Emergency Use Authorization (EUA) by the FDA on February 27, 2021 and recommended by the CDC Advisory Committee on Immunization Practices (ACIP) on February 28, 2021. Find J&J specific materials linked above.

NEW Product Information Guide (v7 issued March 2, 2021)

NEW Ancillary kit syringe and needle deficiency reporting

NEW COVID-19 Vaccine Provider Videos 

Race/Ethnicity Reporting Updates (2/16/21)

Quick Provider Ordering Tips (2/16/21)

VaccineFinder Inventory Reporting in 3 Easy Steps (2/16/21)

Instructions on signing up for ZocDoc (2/8/2021)

CDPH has compiled a provider toolkit which can be used to engage patients and employees eligible for vaccine. Find here under the "toolkits" tab.

NEW  CDPH Provider Update - issued Jan 28, 2021

CDC has issued an MMWR on anaphylaxis reactions for the Pfizer-BioNtech vaccine. 21 cases of anaphylaxis are reported of a total of 1,893,360 vaccine doses administered. 17 of these 21 had a history of allergies or allergic reaction and 7 of these had a history of anaphylaxis. 71% of reported anaphylaxis episodes occurred within the first 15 minutes of vaccination. Read the full report here.

 

Covid-19 Vaccination Chicago Provider Letter from CDPH - posted 12/18/2020

See the CDC site for updated reporting on total administered vaccine doses in the USA.